Sep 23, 2014
By Michael Kramer
A potentially ground-breaking discovery about diabetes – from Toronto’s Mount Sinai Hospital.
A clinical trial has found that a drug – Liraglutide – which mimics a key hormone controlling sugar metabolism – can also preserve pancreatic function and the production of insulin, for at least 48 weeks – in patients with diabetes.
Type 2 diabetes typically worsens progressively – as the ability of the pancreas to produce insulin gradually declines.
The medication is usually reserved for later stages of the disease – but the study results suggest that it should be used much earlier in the course of diabetes – when there is more pancreatic function to preserve.
Principal investigator Doctor Ravi Retnakaran says this discovery has the potential to change the long-term prognosis – for type 2 diabetes.
The findings were just published in the journal “Diabetes Care.”